Destiny Pharma
plc
("Destiny
Pharma" or "the Company")
Result of General Meeting and
Cancellation of Admission to Trading on AIM
Brighton, United
Kingdom - 31 July 2024 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology
company focused on the development and
commercialisation of novel medicines to prevent and cure life
threatening infections, announces that, at the general meeting of
the Company held earlier today (the "General Meeting"), all resolutions put
to the Company's shareholders ("Shareholders") were duly
passed.
The table below sets out the details of the
votes put to Shareholders:
|
Special Resolution Number
|
Special Resolution Name
|
Votes for
|
Votes
Against
|
Votes Withheld*
|
Total Votes Cast (excl. withheld)
|
|
No. of shares
|
% of shares voted
|
No. of shares
|
% of shares voted
|
No. of shares
|
|
1
|
Cancellation Resolution
|
36,177,977
|
87.82%
|
5,016,137
|
12.18%
|
48,982
|
41,194,114
|
|
2
|
Re-registration Resolution
|
36,329,435
|
88.19%
|
4,864,679
|
11.81%
|
48,982
|
41,194,114
|
|
3
|
Adoption of New Articles of Association
Resolution
|
36,183,961
|
87.84%
|
5,010,153
|
12.16%
|
48,982
|
41,194,114
|
*A vote
withheld is not a vote in law and is not counted in the calculation
of the proportion of votes 'For' or 'Against'
In accordance with the passing of Resolutions 2
and 3, the Company will re-register as a private limited company
with the name Destiny Pharma Limited and adopt new articles of
association, which is expected to take place on or around 30 August
2024.
The full text of the resolutions proposed and
passed at the General Meeting can be found in the circular
containing, inter
alia, the Notice of General Meeting, which was published and
posted to Shareholders on 15 July 2024 and is available on the
Company's website www.destinypharma.com
(the "Circular").
AIM
Delisting
Following approval by Shareholders at the
General Meeting, the admission of the ordinary shares of 1 pence
each in the capital of the Company (the "Ordinary Shares") to trading on AIM
will be cancelled (the "AIM
Delisting"). The AIM Delisting is expected to take place at
7.00 a.m. on 13 August 2024 and, accordingly, the last day of
dealings in Ordinary Shares on AIM is expected to be 12 August
2024.
Matched
Bargain Facility
It remains the Company's intention to provide a
matched bargain facility to assist Shareholders wishing to trade in
Ordinary Shares following the AIM Delisting. Further details with
respect to the matched bargain facility, to be provided by J P
Jenkins, will be made available in due course on the Company's
website www.destinypharma.com.
Capitalised terms used but not defined in this
announcement shall have the same meaning given to such terms in the
Circular.
For further
information, please contact:
Destiny Pharma
plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
FTI
Consulting
Ben Atwell / Simon Conway
+44 (0) 203 727 1000
destinypharma@fticonsulting.com
Shore Capital
(Nominated Adviser and Broker)
Daniel Bush / James Thomas / Lucy
Bowden
+44 (0) 207 408 4090
About Destiny
Pharma
Destiny Pharma is an innovative, clinical-stage
biotechnology company focused on the development and
commercialisation of novel medicines that can prevent
life-threatening infections. The Company's drug development
pipeline includes two late-stage assets XF-73 Nasal gel, a
proprietary drug targeting the prevention of post-surgical
staphylococcal hospital infections including MRSA and NTCD-M3, a
microbiome-based biotherapeutic for the prevention of C. difficile
infection (CDI) recurrence which is the leading cause of hospital
acquired infection in the US.
For further information on the company, please visit
www.destinypharma.com